Corrigendum: Inhibition of coronavirus HCoV-OC43 by targeting the eIF4F complex

Front Pharmacol. 2024 Dec 19:15:1528449. doi: 10.3389/fphar.2024.1528449. eCollection 2024.

¹ Cancer Center at Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, United States.
² Conrad Prebys Center for Chemical Genomics at Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, United States.
³ Lady Davis Institute, SMBD Jewish General Hospital, Gerald Bronfman Department of Oncology and Division of Experimental Medicine, McGill University, Montreal, QC, Canada.
⁴ Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA, United States.
⁵ Immunology and Infectious Disease Center at Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, United States.

Abstract

[This corrects the article DOI: 10.3389/fphar.2022.1029093.].

Keywords: A549; COVID-19; OC43; SARS-CoV-2; Vero E6; coronavirus; eIF4F; translation initiation complex.